Guardant Health and Quest Diagnostics will collaborate to offer Guardant’s Shield blood-based colorectal cancer test through ...

Guardant’s screen could see annual sales of $50 billion. The company hopes to use the technology to detect hundreds of other diseases.

A colonoscopy is still the gold standard. It can find and remove precancerous growths during the same procedure, which no ...

Guardant Health, Inc. announced the availability of Shield, the company's first blood-based test for the detection of early-stage colorectal cancer. automation The U.S. Food and Drug Administration on ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

"If I would have known that so many young people were getting diagnosed with colon cancer, I would have taken the symptom ...

A new blood-based test for colorectal cancer currently up for FDA review could mean cheaper and less invasive screenings for the disease. Doctors and advocates have been waiting for years for a new ...

Cologuard is a colon cancer screening test you can do at home. It’s a noninvasive, stool-based test that comes in a kit. You use the kit to collect a stool sample. Then you send the sample to a lab ...

A woman was diagnosed with stage-3 colon cancer at age 24 and said she almost missed a major warning sign of the disease.

Low-dose aspirin use was linked to a 55% lower risk of colorectal cancer recurrence in people with a genetic mutation that ...